Navigation Links
Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
Date:12/10/2007

ng both complete remissions and the fact that the drug has been very well-tolerated."

CPX-351 is a liposomal formulation of cytarabine and daunorubicin delivered in a 5:1 molar ratio shown in preclinical studies to represent a synergistic ratio for use in combination chemotherapy. CPX-351 represents a new approach to developing drug combinations in which drug ratios are pre-selected based on synergistic anti-tumor activity observed preclinically and where the ratios are maintained in patients through Celator's proprietary CombiPlex(TM) technology platform.

"According to the study results, CPX-351 maintained the synergistic ratio of cytarabine and daunorubicin in patients. In addition, evidence of clinical benefit seen in this Phase I study is very encouraging and provides substantial additional support to continue to advance CPX-351 in clinical development," said Andrew Janoff, Ph.D., CEO of Celator.

About Celator

Celator Pharmaceuticals, Inc. is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1, currently in a Phase II trial as a treatment option for colorectal cancer; CPX-351, currently in a Phase I trial as a treatment for leukemia (for information visit http://www.clinicaltrials.gov and search "Celator"); CPX-571, now positioned to advance to Phase I trial and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...nd customer thought leaders -, SAN FRANCISCO, May...ader and trusted resource for clinical trial manag...prestigious academic medical centers, research,ins... group meeting in San,Francisco. The Velos eResear...boratively manage thousands of clinical trials., ...
(Date:5/16/2008)...r PEGylation of a Small Molecule with ...OS, Calif., May 16 /- Nekta...results today from a Phase 1,study of NKTR- 102, P...ti-tumor activity in patients with refractory soli...s small molecule PEGylation technology,produced an...
(Date:5/16/2008)... Significant Reductions in Selected ...ublished in 2008 Proceedings of the American Socie... SAN DIEGO, May 16 /- ADVE... today that, in a registrational bioequivalence,cl... significant reduction,in general disorders and ad...
(Date:5/15/2008)...FirstCall/ -- Medivation, Inc.,(Nasdaq: MDVN ) to...clinical,trial of its novel androgen receptor anta...entation at the 44th American Society of Clinical ...sion title: New Targeted Strategies for Patients w..., June 2 at 11:30 a.m. Central Time Abstract titl...
Breaking Medicine Technology:Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 1PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 2PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 3 2437 million financing for company based on macular degeneration research 3256 1 2437 million financing for company based on macular degeneration research 3256 2Lunch Lady Challenges Schools Families to Make Kids Nutrition a Priority 3251 1Lunch Lady Challenges Schools Families to Make Kids Nutrition a Priority 3251 2Angel Flight West Recognizes Southern California Pilots at 24th Anniversary 3246 1Angel Flight West Recognizes Southern California Pilots at 24th Anniversary 3246 2
(Date:5/16/2008)...EWPORT BEACH, Calif., May 16 /PRNewswire-FirstCall...P ) announced today the promotion of David,M. Boit... Officer. "Dave,has made a tremendous contribution...y our strong investment growth and diversification... over $1 billion in accretive,investments for NHP,...
(Date:5/16/2008)...AN DIEGO, May 16 /PRNewswire-FirstCall/ -- CryoCor...cused on the treatment of cardiac,arrhythmias, ann...ers of,CryoCor common stock filed a complaint in t...ty of San Diego, naming as defendants each member ...Boston Scientific Corporation.,The complaint is st...
(Date:5/16/2008)...ment guidelines quickly disseminated to community ...16 (HealthDay News) -- Partnerships between major ...e a quick and effective way to spread cancer treat... Center in Philadelphia. , Most new cancer trea...ost cancer care is provided at community hospitals...
(Date:5/16/2008)...ismatch in some early stage cases makes therapy of...RIDAY, May 16 (HealthDay News) -- Colon cancer pat...need to receive chemotherapy. In fact, not only do..., it may actually harm them, a new study found. ,...ncer], then you should not be treated with chemoth...
Breaking Medicine News(10 mins):Health News:David M. Boitano Promoted to Senior Vice President 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Partnerships Effective Communicators of Cancer Advances 2Health News:Not All Colon Cancer Patients Need Chemotherapy: Study 2
...eening system combining digital photography with I...method to screen for a common childhood oral disea...ty toddlers. Early childhood dental caries (ECC... tooth decay, results from prolonged exposure to s...
...study published in the journal, Cell Metabolism, r...ion in the zebrafish that are remarkably similar t...es disease that could aid in finding new therapies...ead to the aquarium fish becoming an important ani...
... mothers may someday get a personalized menu of fo...netic makeup as a result of new research at Washin... Researchers used transparent fish embryos to dev...genes and diet interact to cause birth defects. "...
...can children with asthma make more clinic visits t... severity.// Asthma has been on the rise for the ... especially high prevalence. A study in the August...hat Puerto Rican children with asthma make more cl...
Other Medicine News:Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 2Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 3Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 2Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 3Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 4Health News:Unmasking Nutrition's Role in Genes and Birth Defects 2Health News:Unmasking Nutrition's Role in Genes and Birth Defects 3Health News:Children of Different Race Show Different Patterns of Asthma Care 2
Self retaining brain retractor.
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required.
Langenbeck periosteal elevators, wide, blade width 11/16" (17 mm), length 7 1/2" (191 mm).
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm).
Medicine Products: